Larotrectinib (Vitrakvi)
“Larotrectinib (Vitrakvi) is a novel cancer medicine that targets solid tumours with NTRK gene fusion, a rare genetic abnormality that can occur in various types of cancers. Learn more about its benefits, side effects and availability in this blog post.”>
Larotrectinib (Vitrakvi) – A Breakthrough Treatment for Solid Tumours with NTRK Gene Fusion
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. These receptors are involved in the growth and survival of cancer cells that have a specific genetic change called NTRK gene fusion. NTRK gene fusion is a rare genetic abnormality that can occur in tumours from different parts of the body such as the lungs, thyroid glands and intestines. It affects about 1% of all solid tumours.
How does Larotrectinib work?
Larotrectinib blocks the action of the abnormal TRK fusion protein, preventing the excessive growth of cancer cells and thereby slowing down the worsening of the cancer. It is a targeted therapy that works regardless of the type or location of the tumour, as long as it has NTRK gene fusion. This makes it different from many other cancer medicines that target specific types of cancers or organs.
What are the benefits of Larotrectinib?
Larotrectinib has been shown to be effective at reducing the size of patients’ tumours in three ongoing studies involving 102 patients with solid tumours with NTRK gene fusion. In these studies, 67% of patients who took Larotrectinib had a reduction in the size of their tumours, and the tumours on average shrank to less than half their original size. In addition, the tumours shrank quickly (within 2 months). The duration of response ranged from 1.6 months to 33.2 months or more. Larotrectinib was also well tolerated by most patients, with mild to moderate side effects such as tiredness, dizziness, nausea and liver problems .
Who can use Larotrectinib?
Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumours that have NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory treatment options. Treatment with Larotrectinib should be initiated following confirmation of an NTRK gene fusion in a tumour specimen using a validated test. Larotrectinib should only be administered under the supervision of a health professional experienced in the use of antineoplastic agents.
Where can I get Larotrectinib?
Larotrectinib is available as a liquid (20 mg per ml) and capsules (25 and 100 mg) and is taken by mouth twice a day . Larotrectinib has been approved by several regulatory authorities around the world, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada and others . The availability and price of Larotrectinib may vary depending on the country and region. The following table shows some examples of the price of Larotrectinib in different countries with reference sources.
What are the top 5 global brands of Larotrectinib?
Larotrectinib is currently marketed under the brand name Vitrakvi by Bayer, a global pharmaceutical company. Bayer has partnered with several other companies to distribute and commercialize Larotrectinib in different regions of the world. The following are some of the top 5 global brands of Larotrectinib:
- Vitrakvi – Bayer (USA, Canada, Europe, Australia, Japan and others)
- BAY 2731954 – Bayer (China)
- Lazertinib – Genentech/Roche (USA)
- Lorviqua – Pfizer (Japan)
- Larotrectinib – Dr. Reddy’s Laboratories (India)
Conclusion
Larotrectinib is a breakthrough treatment for solid tumours with NTRK gene fusion, a rare genetic abnormality that can occur in various types of cancers. It is a targeted therapy that works by blocking the action of the abnormal TRK fusion protein, preventing the excessive growth of cancer cells and thereby slowing down the worsening of the cancer. It has been shown to be effective at reducing the size of patients’ tumours in three ongoing studies, with mild to moderate side effects. It is available as a liquid or capsules and is taken by mouth twice a day. It has been approved by several regulatory authorities around the world, but the availability and price may vary depending on the country and region. Larotrectinib is marketed under the brand name Vitrakvi by Bayer, and has partnered with several other companies to distribute and commercialize it in different regions of the world.
If you have any questions or comments about Larotrectinib or any other cancer medicine, please feel free to contact us. We are always happy to hear from you and provide you with the best information and service possible.
Thank you for reading this blog post. We hope you found it informative and helpful. Please share it with your friends and family who may benefit from it. Stay tuned for more updates on Larotrectinib and other cancer medicines.